髂静脉支架置入治疗慢性近端静脉流出道梗阻后的二次干预
该单中心回顾性研究纳入490例因慢性近端静脉流出道梗阻接受髂静脉支架置入的患者,平均随访308.59天,二次干预率为10.2%(50/490)。二次干预主要原因包括症状复发(58%)、新发症状(18%)和症状持续(24%),术中常见支架位置异常/成角、急性深静脉血栓/血栓形成、原病变附近新发病灶、支架内狭窄及对侧血流受影响。二次干预后90%患者症状改善。
要点
- 髂静脉支架置入后二次干预率为10.2%,主要原因为症状复发。
- 术中常见发现包括支架内狭窄(38%)和原病变附近新发病灶(68%)。
- 二次干预后90%患者症状改善,支持积极处理并发症。
核心结论
- 髂静脉支架置入治疗慢性PVOO后二次干预率为10.2%,术中发现的可定义异常可作为质量改进靶点。
- 二次干预后90%患者症状改善,提示积极处理这些并发症是合理的。
研究设计与样本
- 单中心回顾性研究,纳入2013年10月至2016年1月因慢性PVOO接受髂静脉支架置入的490例患者。
- 女性57.6%,男性42.4%,平均年龄60.77岁(范围18-92岁),随访率93.28%,平均随访308.59天。
主要发现
- 50/490例(10.2%)接受二次干预,其中58%因症状复发,18%因新发症状,24%因症状持续。
- 二次干预时CEAP分级2、3、4、5、6级患者分别为1、18、17、1、13例。
- PVOO主要病因为外源性髂静脉压迫(52%)、血栓后(28%)和混合性(20%)。
- 术中发现包括支架位置异常/成角(6%)、急性深静脉血栓/血栓形成(14%)、原病变附近新发病灶(68%)、支架内狭窄(38%)及对侧血流受影响(6%)。
- 二次干预方式包括新支架置入(86%)、单纯球囊扩张(10%)和导管药物机械血栓清除(14%)。
临床怎么用
- 髂静脉支架置入后应监测症状复发、新发症状或症状持续,警惕需二次干预。
- 二次干预术中应评估支架位置、血栓、新发病灶及支架内狭窄,并据此选择支架置入、球囊扩张或血栓清除。
局限性
- 单中心回顾性设计,结果外推需谨慎。
- 平均随访时间308.59天,可能低估远期二次干预率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Iliac vein stent placement is an increasingly common procedure in the treatment of chronic proximal venous outflow obstruction (PVOO), but secondary interventions after vein stent placement remain poorly characterized. Our goal was to identify the incidence, indications, operative findings, and outcomes of secondary interventions after the primary iliac vein stent procedure at a single institution. METHODS: We retrospectively reviewed the clinical history of 490 patients (57.6% female, 42.4% male; mean age, 60.77 years [range, 18-92 years]; 93.28% follow-up, with a mean follow-up of 308.59 days) who underwent iliac vein stent placement for PVOO between October 2013 and January 2016. We evaluated the clinical presentation, intraoperative findings, and outcomes of those patients requiring a secondary intervention after an initial iliac vein stent procedure. RESULTS: Secondary interventions after an initial stent placement were identified in 50 of 490 patients (10.2%; mean age, 61.54 years [range, 19-92 years]; 58% female [n = 29]). At the time of each individual intervention, 1, 18, 17, 1, and 13 patients had Clinical, Etiology, Anatomy, and Pathophysiology class 2, 3, 4, 5, and 6 disease, respectively. Of these 50 patients, 58% (n = 29) of secondary interventions were due to recurrence of symptoms after the initial stent surgery, 18% (n = 9) were due to the development of new symptoms, and 24% (n = 12) were due to persistence of symptoms. The primary cause of PVOO in the patient cohort was 52% (n = 26) extrinsic iliac vein compression, 28% post-thrombotic, and 20% mixed. Intraoperative findings during the secondary intervention included malposition or angulation of the stent (6% [n = 3]); acute deep venous thrombosis/thrombosis (14% [n = 7]); an additional lesion, that is, stenosis in a native iliac vein proximal or distal to the original lesion (68% [n = 34]); stenosis within the stent, that is, stent stenosis without finding of thrombus or isolated, focal intrastent thrombosis (38% [n = 19]); and impairment of flow of the contralateral vessel from the previously placed stent (6% [n = 3]). The types of secondary interventions included placement of a new stent (86% [n = 43]), isolated balloon angioplasty alone (10% [n = 5]), and catheter pharmacomechanical thrombectomy (14% [n = 7]). Symptomatic improvement was observed after the secondary intervention in 90% of patients (n = 45), whereas only 2% (n = 1) of patients experienced only a transient improvement, and 8% of patients (n = 4) reported no improvement in their symptoms after the secondary interventions. CONCLUSIONS: This study establishes a secondary intervention rate of 10.2% after iliac vein stent placement for chronic PVOO and identifies discrete and definable intraoperative findings as targets for quality improvement. The very good results strongly suggest that an aggressive approach to treatment of these complications is warranted.
引用
- Aboubakr A, Chait J, Lurie J, et al. Secondary interventions after iliac vein stenting for chronic proximal venous outflow obstruction. J Vasc Surg Venous Lymphat Disord. 2019. PMID: 31068276. doi:10.1016/j.jvsv.2019.02.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。